S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Spero Therapeutics Stock Forecast, Price & News

-0.12 (-0.85%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
53,531 shs
Average Volume
172,077 shs
Market Capitalization
$454.15 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Spero Therapeutics logo

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.


SPRO.P - Profile | Reuters
November 4, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$9.33 million
Book Value
$3.46 per share


Net Income
$-78.28 million
Net Margins
Pretax Margin




Free Float
Market Cap
$454.15 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.44 out of 5 stars

Medical Sector

157th out of 1,394 stocks

Pharmaceutical Preparations Industry

66th out of 674 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

Is Spero Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spero Therapeutics stock.
View analyst ratings for Spero Therapeutics
or view top-rated stocks.

How has Spero Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SPRO shares have increased by 81.3% and is now trading at $14.05.
View which stocks have been most impacted by COVID-19

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Spero Therapeutics

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.04. The firm had revenue of $3.06 million for the quarter, compared to the consensus estimate of $3 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 69.84% and a negative net margin of 454.11%. During the same quarter in the prior year, the firm posted ($0.86) EPS.
View Spero Therapeutics' earnings history

What price target have analysts set for SPRO?

4 Wall Street analysts have issued 1 year price targets for Spero Therapeutics' shares. Their forecasts range from $40.00 to $70.00. On average, they anticipate Spero Therapeutics' stock price to reach $52.33 in the next twelve months. This suggests a possible upside of 272.5% from the stock's current price.
View analysts' price targets for Spero Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:
  • Ankit A. Mahadevia, President, Chief Executive Officer & Director
  • Cristina Larkin, Chief Operating Officer
  • Satyavrat Shukla, Treasurer, Chief Financial & Accounting Officer
  • Thomas R. Parr, Chief Scientific Officer
  • Troy Lister, Senior Vice President-Research & Development

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (5.63%), BlackRock Inc. (5.61%), Rock Springs Capital Management LP (2.93%), Granahan Investment Management Inc. MA (1.73%), Geode Capital Management LLC (1.38%) and Dimensional Fund Advisors LP (1.03%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics

Which major investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Dimensional Fund Advisors LP, Rock Springs Capital Management LP, Citigroup Inc., California State Teachers Retirement System, Morgan Stanley, Russell Investments Group Ltd., and Advisor Group Holdings Inc.. Company insiders that have sold Spero Therapeutics company stock in the last year include Aquilo Capital Management, Llc, and Cristina Larkin.
View insider buying and selling activity for Spero Therapeutics
or view top insider-selling stocks.

Which major investors are buying Spero Therapeutics stock?

SPRO stock was acquired by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Royal Bank of Canada, Brandywine Global Investment Management LLC, Bourgeon Capital Management LLC, Geode Capital Management LLC, UBS Group AG, BlackRock Inc., and New York State Common Retirement Fund.
View insider buying and selling activity for Spero Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $14.05.

How much money does Spero Therapeutics make?

Spero Therapeutics has a market capitalization of $454.15 million and generates $9.33 million in revenue each year. The company earns $-78.28 million in net income (profit) each year or ($2.67) on an earnings per share basis.

How many employees does Spero Therapeutics have?

Spero Therapeutics employs 89 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

Where are Spero Therapeutics' headquarters?

Spero Therapeutics is headquartered at 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 242-1600 or via email at [email protected].

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.